DPDaily Peptide

RETATRUTIDE · DECODED

← Back to Decoded
#1 FAT BURNERTRIPLE AGONIST · GLP-1 / GIP / GCG

Retatrutide

Decoded · Eli Lilly LY3437943 · Investigational

Same receptor class. Different mechanism. Higher measured weight loss. Retatrutide suppresses appetite, improves glucose metabolism, and increases fat oxidation at the receptor level — three mechanisms in one molecule. The Phase 3 data produced weight loss figures higher than any previously recorded in a GLP-1 trial.

BY THE NUMBERS

28.7%
AVG BODY WEIGHT LOSS AT 12 MG / 68 WK
71.2 lb
PEAK WEIGHT LOSS TRIUMPH-4 TRIAL
3-in-1
RECEPTOR AGONISM GLP-1 · GIP · GCG
5,800+
PARTICIPANTS ACROSS THE 4 TRIUMPH REGISTRATIONAL TRIALS

HOW IT WORKS

Simultaneously activates three receptors: GLP-1, GIP, and glucagon (GCG). GLP-1 and GIP suppress appetite and improve insulin response; glucagon drives active fat oxidation at the metabolic level. Retatrutide is the only compound in the class that burns fat at the receptor level rather than solely reducing caloric intake.

WHERE IT CAME FROM

Retatrutide (LY3437943) is an investigational once-weekly peptide developed by Eli Lilly & Co., the same company behind Mounjaro and Zepbound. Where semaglutide hits one receptor (GLP-1) and tirzepatide hits two (GLP-1 + GIP), Retatrutide is the first triple hormone receptor agonist, adding glucagon (GCG) into the mix.

The glucagon arm is the difference-maker. Glucagon at controlled levels increases energy expenditure and shifts the body toward fat oxidation, meaning Retatrutide doesn't just suppress appetite. It actively burns fat at the metabolic level. The Phase 3 TRIUMPH program kicked off in 2023; the first registrational results landed December 2025.

THE STUDIES

2023
Phase 2 (NEJM): The Phase 2 trial enrolled adults with obesity and tested retatrutide at multiple doses over 24 weeks. The 12 mg dose produced an average of 17.5% body weight loss at 24 weeks, which already surpassed the best results seen from any approved GLP-1 drug at equivalent timepoints. A commonly cited figure of 24% reflects a full-curve projection from this data, not a direct trial endpoint. The Phase 2 results were sufficient to accelerate Eli Lilly into a full Phase 3 program. Source: Jastreboff et al., NEJM 2023.
Dec 2025
TRIUMPH-4 (Phase 3): TRIUMPH is Eli Lilly's Phase 3 trial program for retatrutide, covering obesity, type 2 diabetes, and several related conditions. TRIUMPH-4 specifically enrolled adults with obesity and knee osteoarthritis, a joint condition where excess weight accelerates cartilage breakdown and pain. At 68 weeks on the 12 mg dose, participants lost an average of 28.7% of body weight (71.2 lbs from a mean baseline of 248.5 lbs). The WOMAC scale measures knee pain and function on a standardized score. Participants saw a 75.8% reduction in their pain score versus 40.3% with placebo. In a post-hoc analysis, approximately 1 in 8 retatrutide-treated participants reported being completely free of knee pain at week 68, compared with just over 4% of placebo recipients.
Mar 2026
TRANSCEND-T2D-1: TRANSCEND-T2D-1 was a Phase 3 trial testing retatrutide in adults with type 2 diabetes. HbA1c, or hemoglobin A1c, is a blood marker that reflects average blood sugar over roughly three months. A reduction of 1% is considered clinically meaningful in diabetes management. Retatrutide produced HbA1c reductions of 1.7 to 2.0% at 40 weeks, alongside 16.8% body weight loss.
May 2026
TRIUMPH-1 (Phase 3): TRIUMPH-1 was the largest trial in the TRIUMPH program, enrolling 2,339 participants with obesity over 80 weeks. At the 12 mg dose, average body weight loss reached 25.0%. In participants with severe obesity, the figure reached 30%, a threshold previously associated only with bariatric surgery. Results were announced May 21, 2026. Source: Eli Lilly press release; The Pharmaceutical Journal, May 22, 2026.
Ongoing
Six additional TRIUMPH trials pending: The remaining TRIUMPH trials cover sleep apnea, chronic back pain, metabolic liver disease, cardiovascular and kidney outcomes, and a lower-dose maintenance study at 4 mg. Results are expected to read out through 2026 and into 2027.

WHAT THE STUDIES SHOW

WEIGHT LOSS

  • ▸58.6% hit ≥25% loss (12 mg dose, TRIUMPH-4)
  • ▸39.4% hit ≥30% loss (12 mg dose, TRIUMPH-4)
  • ▸23.7% hit ≥35% loss (12 mg dose, TRIUMPH-4)
  • ▸Rivals bariatric surgery

CARDIOMETABOLIC

  • ▸↓ Non-HDL cholesterol
  • ▸↓ Triglycerides
  • ▸↓ Systolic blood pressure
  • ▸↓ Blood sugar (A1C) 1.7–2.0% (TRANSCEND-T2D-1)

BEYOND WEIGHT

  • ▸↓ Knee arthritis pain, 75.8%
  • ▸Improved physical function
  • ▸Trials in metabolic liver disease and sleep apnea
  • ▸Chronic back pain trial

SIDE EFFECTS

COMMON (TITRATION PHASE)

  • ▸Nausea (~43%)
  • ▸Diarrhea (~33%)
  • ▸Vomiting, decreased appetite
  • ▸Constipation, fatigue
  • ▸Most resolve as body adapts

NOTABLE / LESS COMMON

  • ▸Dysesthesia (skin tingling) ~20.9%
  • ▸Mild HR elevation (glucagon arm)
  • ▸Injection site reactions
  • ▸Discontinuation: 2.2-5.1%
  • ▸No major safety signals to date

REGULATORY STATUS

FDA STATUS
Not approved · Investigational · Classification disputed
PHASE
Phase 3 · TRIUMPH program · Ongoing
PROJECTED NDA
Disputed · Timeline unclear

Retatrutide is not FDA approved and its regulatory path forward is currently contested in a way that has no clear precedent in the GLP-1 class. The dispute centers on a structural question: what kind of molecule is it? Retatrutide has 39 amino acids. The FDA draws the line at 40. Anything below that threshold is classified as a small-molecule drug, not a biologic, and that distinction carries enormous commercial consequences. Biologics, which are drugs composed of larger or more complex molecules, receive a separate and longer form of market exclusivity that makes them significantly harder for competitors to copy. Small-molecule drugs do not get that protection, which means generic versions can enter the market sooner after approval. Eli Lilly is arguing that retatrutide should be classified as a biologic anyway. The company's case rests on the C-20 fatty acid chain attached to the molecule's structure. Eli Lilly contends that this modification, because of its size and complexity, should be counted in a way that pushes the effective molecular count over the 40-unit threshold, placing retatrutide in biologic territory under a more expansive reading of the regulatory definition. The FDA has not accepted that argument. If the agency holds its position, retatrutide gets approved as a small-molecule drug with shorter exclusivity protections, and the door opens to generic competition earlier than Eli Lilly would prefer. The Phase 3 TRIUMPH trial program is actively running and the science behind the molecule is not in dispute. What remains unresolved is the legal and regulatory category it lands in, and that determination will shape retatrutide's commercial future as much as any trial result.

PROS & CONS

PROS

  • +Highest weight loss ever recorded in a Phase 3 trial
  • +Triple mechanism: appetite, metabolism, and fat oxidation
  • +Cardiometabolic improvements beyond weight
  • +Pain reduction (knee arthritis), sleep apnea benefits
  • +Once-weekly dosing
  • +Backed by Lilly's manufacturing and trial pipeline

CONS

  • −Not FDA approved, research grade only
  • −GI side effects common during titration
  • −Glucagon arm may elevate HR / BP in some
  • −Long-term safety data still being collected
  • −Cost & supply unknown post-approval
  • −Muscle loss risk if not paired with protein/training

DAILY PEPTIDE VERDICT

RANKING

The Class Ceiling

Retatrutide represents a new tier within the class. It's not just an upgrade to semaglutide or tirzepatide — it's a different mechanism. The triple-agonist approach produces weight loss that rivals bariatric surgery without the operating room. It's still pre-approval. GI side effects are real during titration, and the glucagon arm produces mild resting heart rate elevation not seen with semaglutide or tirzepatide. The Phase 3 data is the basis for where it sits in the class.

Also in WEIGHT LOSS

// WEIGHT LOSS

Semaglutide

FDA APPROVEDPHASE 3+

// WEIGHT LOSS

Tirzepatide

FDA APPROVEDPHASE 3+

DISCLAIMER · EDUCATIONAL USE ONLY

This document is for educational and informational purposes only. Retatrutide does not hold general FDA approval for human use. Information here synthesizes publicly available research data and does not constitute medical advice.